Chairpersons :

Shishir Shetty, S. D. Banavali, Anil Sanganeria

Reviewer :

Neelesh Reddy

1. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial Author: Colleoni M. Citation: Lancet Oncol. 2018 Jan;19(1):127-138

2. Primary results of LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative Early Breast Cancer (EBC) Author: Saura C. Citation: SMO LBA10_PR